Latest news with #IPN
The Print
10-05-2025
- Health
- The Print
Johnson & Johnson Medtech Partners with Qure.ai to Boost Early Detection of Lung Cancer in India
Mumbai (Maharashtra) [India], May 9: Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded a global leader in artificial intelligence (AI) for healthcare, as a strategic partner with Johnson & Johnson Private Limited, a Johnson & Johnson company, to enhance early detection of lung cancer in India. This collaboration brings together cutting-edge AI and medical technology, helping identify lung cancer at its most treatable stage. This initiative is part of Project BreatheEZ, a broader strategic collaboration between and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, AI technology will be deployed across 10 hub medical centers in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu. In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 2025¹. This growing health challenge needs innovative solutions to improve early detection and ultimately save lives. Traditional diagnostic methods often fail to detect lung cancer at an early stage, leading to delays in treatment. Thus, this collaboration between Johnson & Johnson MedTech and marks a significant leap forward. By harnessing of artificial intelligence in the modalities of X-Ray & CT scans, Johnson & Johnson MedTech India & are enabling the detection of potential lung nodules that might otherwise be missed. This happens through flagging risky nodules in X-Rays and CT Scans that can potentially turn out to be malignant. It also introduces the concept of structured IPN clinics where there is a proactive impetus towards incidental screening of early-stage lung cancer. This partnership embodies Johnson & Johnson MedTech's commitment to enhancing early lung cancer detection, ultimately transforming the standard of lung cancer care. Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, 'Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.' Reference: 1. ICMR and NCDIR World Cancer Day 2024, Close the care gap- Addressing cancer care in India, 04th – February – 2024 Surgical Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what's next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. For more, visit (ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same) This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content.
Time of India
08-05-2025
- Health
- Time of India
J&J Medtech, Qure.ai partner to boost early detection of lung cancer in India
Mumbai: Johnson & Johnson MedTech announced its collaboration with as a strategic partner with Johnson & Johnson Private Limited, to enhance early detection of lung cancer in India to bring together cutting-edge AI and medical technology which will help identify lung cancer at its most treatable stage. This initiative is part of Project BreatheEZ , a broader strategic collaboration between and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, AI technology will be deployed across 10 hub medical centers in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu, stated the press release. In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 20251. This growing health challenge needs innovative solutions to improve early detection and ultimately save lives. Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, 'Our collaboration with is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.'
Yahoo
06-05-2025
- Business
- Yahoo
Paymentus to Participate in Upcoming Investor Conferences in May and June
CHARLOTTE, N.C., May 06, 2025--(BUSINESS WIRE)--Paymentus Holdings, Inc. ("Paymentus") (NYSE: PAY), a leading provider of cloud-based bill payment technology solutions, today announced that Dushyant Sharma, Chief Executive Officer, and Sanjay Kalra, Chief Financial Officer, will participate in the following investor conferences: J.P. Morgan 2025 Global Technology, Media and Communications Conference in Boston on Tuesday, May 13 th , where Mr. Sharma and Mr. Kalra will participate in a fireside chat at 4:30 pm ET Baird Global Consumer, Technology & Services Conference on Tuesday, June 3 rd in New York Wolfe Research Small and Mid-Cap Conference on Wednesday, June 4th A live webcast and replay of the J.P. Morgan fireside chat will be available on Paymentus' investor relations website at Management will host investor meetings throughout the day. For further information, please contact your J.P. Morgan, Baird, or Wolfe Research representative or email paymentus@ About Paymentus Paymentus is a leading provider of cloud-based bill payment technology and solutions for more than 2,500 billers and financial institutions across North America. Our omni-channel platform provides consumers with easy-to-use, flexible and secure electronic bill payment experiences through their preferred payment channel and type. Paymentus' proprietary Instant Payment NetworkTM, or IPN, extends our reach by connecting our IPN partners' platforms and tens of thousands of billers to our integrated billing, payment, and reconciliation capabilities. For more information, please visit CATEGORY: CORPORATE NEWS View source version on Contacts Investor Contact: David Hanover, Senior Vice President KCSA Strategic Communications paymentus@ Media Contact: Jon Goldberg KCSA Strategic Communications jgoldberg@
Business Wire
06-05-2025
- Business
- Business Wire
Paymentus to Participate in Upcoming Investor Conferences in May and June
CHARLOTTE, N.C.--(BUSINESS WIRE)--Paymentus Holdings, Inc. ('Paymentus') (NYSE: PAY), a leading provider of cloud-based bill payment technology solutions, today announced that Dushyant Sharma, Chief Executive Officer, and Sanjay Kalra, Chief Financial Officer, will participate in the following investor conferences: J.P. Morgan 2025 Global Technology, Media and Communications Conference in Boston on Tuesday, May 13 th , where Mr. Sharma and Mr. Kalra will participate in a fireside chat at 4:30 pm ET , where Mr. Sharma and Mr. Kalra will participate in a fireside chat at 4:30 pm ET Baird Global Consumer, Technology & Services Conference on Tuesday, June 3 rd in New York in New York Wolfe Research Small and Mid-Cap Conference on Wednesday, June 4th A live webcast and replay of the J.P. Morgan fireside chat will be available on Paymentus' investor relations website at Management will host investor meetings throughout the day. For further information, please contact your J.P. Morgan, Baird, or Wolfe Research representative or email paymentus@ About Paymentus Paymentus is a leading provider of cloud-based bill payment technology and solutions for more than 2,500 billers and financial institutions across North America. Our omni-channel platform provides consumers with easy-to-use, flexible and secure electronic bill payment experiences through their preferred payment channel and type. Paymentus' proprietary Instant Payment NetworkTM, or IPN, extends our reach by connecting our IPN partners' platforms and tens of thousands of billers to our integrated billing, payment, and reconciliation capabilities. For more information, please visit CATEGORY: CORPORATE NEWS
Yahoo
30-04-2025
- Business
- Yahoo
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
Information relating to the holding of the Combined Shareholders' Meeting of 21 May 2025 of Ipsen FRANCE, 30 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 21 May 2025 at 3:00 p.m. (Paris time) at the Salons de l'Hôtel des Arts et Métiers, 9 bis avenue d'Iéna, 75116 Paris. The preliminary notice of the Meeting ('avis de réunion') was published in the Bulletin des Annonces Légales Obligatoires (BALO) of 11 April 2025 and the notice of Meeting ('avis de convocation') was published in the BALO on 30 April 2025. These documents, as well as the Convening notice (including the agenda, the draft resolutions and the conditions regarding attendance and vote), are also available on Ipsen's website at the following address: under the Investors / Regulated Information / Shareholders Meeting section. Documents and information relating to this Meeting are made available to shareholders under the legal and regulatory conditions in force. The Shareholders will be asked to approve in particular the following resolutions: The payment of a dividend of €1.40 per share for the 2024 financial year, the ex-date being set on 4 June 2025 and the dividend payment on 6 June 2025; The renewals of the terms of office of Mr. David LOEW, Mr. Antoine FLOCHEL, Mrs. Margaret LIU and Mrs. Karen WITTS as Directors for a term of 4 years, maintaining the independence Directors' rate within the Board of Directors at a third in accordance with the Afep-Medef Code and each gender's proportion at more than 40% in accordance with the law (Directors representing the employees being not taken into account in these rates). In accordance with applicable regulatory provisions: Registered shareholders may, up to the fifth day (inclusive) before the Meeting, request from the Company to send these documents, where appropriate at his/her express request by electronic means. For holders of bearer shares, the exercise of this right is subject to the presentation of a shareholding certificate (attestation de participation) in the bearer securities accounts managed by the authorized intermediary. Any shareholder may consult these documents at the Company's headquarters. ENDS About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen contacts Investors Khalid DEOJEE | + 33 6 66 01 95 26 | Media Sally BAIN | + 1 857 320 0517 | Anne LIONTAS | + 33 7 67 34 72 96 | Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment Documents availability - 2025 Ipsen Combined Shareholder's MeetingSign in to access your portfolio
